Junshi Biosciences Licenses IL-17A Monoclonal Antibody Nokoriximab to Fosun Pharma’s Subsidiary for Greater China with Deal Value Up to RMB 1.34 Billion

Source: Corporate Official Website

Pursuant to the licensing agreement, Junshi Biosciences grants Jiangsu Wanbang Biopharmaceuticals a license regarding Rucocipat monoclonal antibody(JS005, anti-IL-17A monoclonal antibody)AtGreater China Region(including mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan)ofRights to Development, Registration, Manufacturing, and Commercialization。

Tucokizumab is a specific anti-IL-17A Monoclonal AntibodyBy binding with high affinity to the IL-17A homodimer and the IL-17A/IL-17F heterodimer, and selectively blocking the interaction between IL-17A and its receptor complex IL-17RA/IL-17RC, it inhibits the activation of downstream signaling pathways and the release of inflammatory cytokines, thereby effectively alleviating the symptoms of autoimmune diseases.

Currently, Ronacizumab has beenModerate to Severe Plaque PsoriasisCompletion of China Registration in Adult PatientsPhase IIIclinical studies, demonstrating excellent efficacy and safety. In the 150 mg dose group, at Week 16PASI 90 response rate reached 91%; At Week 52PASI 100 Response Rate Reached 65%。

In December 2025, rocapulimab was used for the treatment ofNMPA Accepts New Drug Application for Adult Patients with Moderate-to-Severe Plaque Psoriasis Suitable for Systemic Therapy or Phototherapy。

Under the agreement, Junshi Biosciences will receive RMB215 million yuan(Tax included)Non-deductible and non-refundable down payment, with eligibility for up to RMBRMB 1.125 billion(Tax included)development and sales milestone payments, as well as tiered sales royalties amounting to a double-digit percentage of net sales in the Greater China region.Milestone payments for product development amount to up to RMB 180 million.(Tax Included), sales milestone payments up to RMB 945 million(Including Tax)。

According to statistics from the Insight database,The IL-17 therapeutic landscape in China is already highly crowded.Currently, a total of 6 IL-17A monospecific drugs have been approved for marketing., including2 Imported Drugs, Secukinumab(Novartis)andIxekizumab(Eli Lilly), and4 Domestic Drugs, Gomocizumab(Akeso), Funakizumab(Hengrui), Seliciximab(Zhixiang Jintai)and Anmuzhitamab(Sansheng Guojian). Furthermore, UCB has an IL-17A/F monoclonal antibody that has already been approved for marketing in China; this drug is2025Emerging as the "dark horse" in the Top 100 Global Pharmaceutical Sales Rankings with a year-on-year growth rate of 285.17%.